Overview
Identified vs. credited
Cumulative overbilling found and credits received, by month
Upload checklist
Files due by the 10th of each month
- Nov 2026Due Dec 10
- Oct 2026Invoices · Nov 6 Census · Nov 9
- Sep 2026Invoices · Oct 8 Census · late Oct 15
- Aug 2026Invoices · Sep 8 Census · Sep 9
- Jul 2026Invoices · Aug 6 Census · Aug 7
- Jun 2026Invoices · Jul 7 Census · Jul 9
- May 2026Invoices · Jun 5 Census · Jun 8
Findings by category
Overbilling identified each month
October 2026: $44.64 facility-paid outside Part A (0.2% of facility drug charges, 1 line); $44.64 flagged.
Contract watch
Northbridge Institutional Pharmacy (fictional)
- New fee patternAfter-hours surcharge billed since August 2026; not in the agreement$600.00 flagged across 3 months, $0.00 credited. The agreement does not list this fee or allow unlisted fees. Raise it with the pharmacy at contract level, not only invoice by invoice.
- Amendment 1STAT delivery fee raised from $35.00 to $45.00 (+29%)In force from August 2026. 9 billed since, $90.00 more than the old rate. Every charge since matches the amended rate and monthly cap.
- Credits overdue3 disputed items past the 30-day credit follow-up$404.02 still owed. Follow up with the pharmacy's billing contact.
Open disputes
10 items with credit still owed · as of Nov 9, 2026
| Finding | Resident | Amount | Credited | Status | Due |
|---|---|---|---|---|---|
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Aug 2026 · Payer misbilling | R1069 | $41.56 | $0.00 | Disputed | Oct 13, 202627 days overdue Credit expected by |
After-hours surcharge fee: fee type not listed in the pharmacy services agreement (2026-08) F4-001 · Aug 2026 · Fees against contract | Facility-level | $200.00 | $0.00 | Disputed | Oct 13, 202627 days overdue Credit expected by |
Retroactive Medicaid eligibility: credit due for charges fronted while pending F8-001 · Aug 2026 · Outside Part A | R1173 | $162.46 | $0.00 | Disputed | Oct 13, 202627 days overdue Credit expected by |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Sep 2026 · Payer misbilling | R1008 | $493.90 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
Charges dated after discharge F2-001 · Sep 2026 · After discharge or death | R1129 | $265.92 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
After-hours surcharge fee: fee type not listed in the pharmacy services agreement (2026-09) F4-001 · Sep 2026 · Fees against contract | Facility-level | $250.00 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
Possible hospice responsibility: drugs billed to the facility during hospice care F8-003 · Sep 2026 · Outside Part A | R1076 | $25.83 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Oct 2026 · Payer misbilling | R1035 | $47.14 | $0.00 | Not yet disputed | Jan 29, 2027in 81 days Dispute window closes |
All findings
Every finding from every monthly run, with where it stands
| Finding | Type | Resident | Amount | Credited | Status | Due / resolved |
|---|---|---|---|---|---|---|
After-hours surcharge fee: fee type not listed in the pharmacy services agreement (2026-10) F4-001 · Oct 2026 · Fees against contract | Overbilling | Facility-level | $150.00 | $0.00 | Not yet disputed | Jan 29, 2027in 81 days Dispute window closes |
Duplicate charge: Lorazepam 0.5 mg TAB F3-001 · Oct 2026 · Duplicates and credits | Overbilling | R1169 | $22.05 | $0.00 | Not yet disputed | Jan 29, 2027in 81 days Dispute window closes |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Oct 2026 · Payer misbilling | Overbilling | R1035 | $47.14 | $0.00 | Not yet disputed | Jan 29, 2027in 81 days Dispute window closes |
Part D billed during a Medicare Part A stay C1-001 · Oct 2026 · Part D during Part A | Part A exposure | R1163 | $407.68 | — | Needs correction | — |
Possible hospice responsibility: drugs billed to the facility during hospice care F8-003 · Sep 2026 · Outside Part A | Overbilling | R1076 | $25.83 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
Part D rejection passed to the facility: non-formulary (avoidable rejection, review) F8-002 · Sep 2026 · Outside Part A | Overbilling | R1078 | $240.64 | $240.64 | Credited | Resolved Oct 24, 2026 |
Part D rejection passed to the facility: prior authorization required (avoidable rejection, review) F8-001 · Sep 2026 · Outside Part A | Overbilling | R1072 | $362.86 | $362.86 | Credited | Resolved Oct 25, 2026 |
After-hours surcharge fee: fee type not listed in the pharmacy services agreement (2026-09) F4-001 · Sep 2026 · Fees against contract | Overbilling | Facility-level | $250.00 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
Charges dated after discharge F2-001 · Sep 2026 · After discharge or death | Overbilling | R1129 | $265.92 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Sep 2026 · Payer misbilling | Overbilling | R1008 | $493.90 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
Part D billed during a Medicare Part A stay C1-001 · Sep 2026 · Part D during Part A | Part A exposure | R1149 | $661.44 | — | Needs correction | — |
OTC priced above contract: Bisacodyl 5 mg TAB EC (OTC) F8-002 · Aug 2026 · Outside Part A | Overbilling | R1071 | $1.80 | $1.80 | Credited | Resolved Sep 25, 2026 |
Retroactive Medicaid eligibility: credit due for charges fronted while pending F8-001 · Aug 2026 · Outside Part A | Overbilling | R1173 | $162.46 | $0.00 | Disputed | Oct 13, 202627 days overdue Credit expected by |
After-hours surcharge fee: fee type not listed in the pharmacy services agreement (2026-08) F4-001 · Aug 2026 · Fees against contract | Overbilling | Facility-level | $200.00 | $0.00 | Disputed | Oct 13, 202627 days overdue Credit expected by |
Duplicate charge: Sertraline 50 mg TAB F3-001 · Aug 2026 · Duplicates and credits | Overbilling | R1121 | $19.53 | $19.53 | Credited | Resolved Sep 25, 2026 |
Charges dated after death F2-001 · Aug 2026 · After discharge or death | Overbilling | R1118 | $233.00 | $233.00 | Credited | Resolved Sep 25, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Aug 2026 · Payer misbilling | Overbilling | R1069 | $41.56 | $0.00 | Disputed | Oct 13, 202627 days overdue Credit expected by |
Part D billed during a Medicare Part A stay C1-001 · Aug 2026 · Part D during Part A | Part A exposure | R1134 | $483.60 | — | Corrected | Resolved Sep 29, 2026 |
Duplicate charge: Aspirin 81 mg TAB EC F3-001 · Jul 2026 · Duplicates and credits | Overbilling | R1114 | $0.56 | $0.56 | Credited | Resolved Aug 27, 2026 |
Charges dated after death F2-002 · Jul 2026 · After discharge or death | Overbilling | R1110 | $233.00 | $233.00 | Credited | Resolved Aug 27, 2026 |
Charges dated after discharge F2-001 · Jul 2026 · After discharge or death | Overbilling | R1102 | $376.47 | $376.47 | Credited | Resolved Aug 16, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-002 · Jul 2026 · Payer misbilling | Overbilling | R1018 | $35.98 | $35.98 | Credited | Resolved Aug 22, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Jul 2026 · Payer misbilling | Overbilling | R1058 | $562.36 | $562.36 | Credited | Resolved Sep 5, 2026 |
Part D billed during a Medicare Part A stay C1-001 · Jul 2026 · Part D during Part A | Part A exposure | R1121 | $465.92 | — | Corrected | Resolved Aug 27, 2026 |
Priced above contract: Eliquis 5 mg TAB F6-001 · Jun 2026 · Price against contract | Overbilling | Facility-level | $149.35 | $149.35 | Credited | Resolved Jul 20, 2026 |
CB-excluded drug billed to facility during Part A: Leuprolide Acetate 22.5 mg DEPOT KIT F5-001 · Jun 2026 · Consolidated billing | Overbilling | R1108 | $1,596.00 | $1,596.00 | Credited | Resolved Aug 19, 2026 |
Delivery fee: charged above the contract rate (2026-06) F4-002 · Jun 2026 · Fees against contract | Overbilling | Facility-level | $40.00 | $40.00 | Credited | Resolved Aug 4, 2026 |
Packaging fee: fee type not listed in the pharmacy services agreement (2026-06) F4-001 · Jun 2026 · Fees against contract | Overbilling | Facility-level | $45.00 | $45.00 | Credited | Resolved Aug 21, 2026 |
Duplicate charge: Amlodipine 5 mg TAB F3-002 · Jun 2026 · Duplicates and credits | Overbilling | R1032 | $11.48 | $11.48 | Credited | Resolved Jul 21, 2026 |
Duplicate charge: Levothyroxine 50 mcg TAB F3-001 · Jun 2026 · Duplicates and credits | Overbilling | R1117 | $14.99 | $14.99 | Credited | Resolved Sep 9, 2026 |
Charges dated after discharge F2-003 · Jun 2026 · After discharge or death | Overbilling | R1096 | $224.76 | $224.76 | Credited | Resolved Jul 16, 2026 |
Charges dated after discharge F2-002 · Jun 2026 · After discharge or death | Overbilling | R1098 | $265.92 | $265.92 | Credited | Resolved Aug 25, 2026 |
Charges dated after discharge F2-001 · Jun 2026 · After discharge or death | Overbilling | R1085 | $265.92 | $265.92 | Credited | Resolved Jul 22, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-003 · Jun 2026 · Payer misbilling | Overbilling | R1069 | $40.30 | $40.30 | Credited | Resolved Jul 19, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-002 · Jun 2026 · Payer misbilling | Overbilling | R1060 | $40.30 | $40.30 | Credited | Resolved Sep 13, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Jun 2026 · Payer misbilling | Overbilling | R1022 | $493.90 | $493.90 | Credited | Resolved Sep 6, 2026 |
Part D billed during a Medicare Part A stay C1-002 · Jun 2026 · Part D during Part A | Part A exposure | R1110 | $341.76 | — | Corrected | Resolved Jul 29, 2026 |
Part D billed during a Medicare Part A stay C1-001 · Jun 2026 · Part D during Part A | Part A exposure | R1111 | $508.80 | — | Corrected | Resolved Jul 29, 2026 |
Priced above contract: Pantoprazole 40 mg TAB EC F6-001 · May 2026 · Price against contract | Overbilling | Facility-level | $195.20 | $119.04 | Written off | Resolved Jul 19, 2026 |
CB-excluded drug billed to facility during Part A: Epoetin Alfa 10,000 unit/mL VIAL F5-002 · May 2026 · Consolidated billing | Overbilling | R1096 | $117.60 | $117.60 | Credited | Resolved Jun 22, 2026 |
CB-excluded drug billed to facility during Part A: Leuprolide Acetate 22.5 mg DEPOT KIT F5-001 · May 2026 · Consolidated billing | Overbilling | R1095 | $1,596.00 | $1,596.00 | Credited | Resolved Jul 9, 2026 |
Packaging fee: fee type not listed in the pharmacy services agreement (2026-05) F4-004 · May 2026 · Fees against contract | Overbilling | Facility-level | $45.00 | $45.00 | Credited | Resolved Jul 20, 2026 |
Stat delivery fee: charged more often than the contract allows (2026-05) F4-003 · May 2026 · Fees against contract | Overbilling | Facility-level | $70.00 | $0.00 | Denied | Resolved Jul 6, 2026 |
Delivery fee: charged above the contract rate (2026-05) F4-002 · May 2026 · Fees against contract | Overbilling | Facility-level | $100.00 | $100.00 | Credited | Resolved Aug 4, 2026 |
Dispensing fee: charged above the contract rate (2026-05) F4-001 · May 2026 · Fees against contract | Overbilling | Facility-level | $365.00 | $365.00 | Credited | Resolved Jul 5, 2026 |
Duplicate charge: Furosemide 40 mg TAB F3-004 · May 2026 · Duplicates and credits | Overbilling | R1093 | $5.58 | $5.58 | Credited | Resolved Jul 24, 2026 |
Duplicate charge: Donepezil 10 mg TAB F3-003 · May 2026 · Duplicates and credits | Overbilling | R1093 | $27.72 | $27.72 | Credited | Resolved Jul 19, 2026 |
Duplicate charge: Jardiance 10 mg TAB F3-002 · May 2026 · Duplicates and credits | Overbilling | R1100 | $325.08 | $325.08 | Credited | Resolved Aug 10, 2026 |
Duplicate charge: Eliquis 5 mg TAB F3-001 · May 2026 · Duplicates and credits | Overbilling | R1083 | $510.38 | $510.38 | Credited | Resolved Jun 18, 2026 |
Charges dated after discharge F2-006 · May 2026 · After discharge or death | Overbilling | R1086 | $226.01 | $226.01 | Credited | Resolved Jul 23, 2026 |
Charges dated after discharge F2-005 · May 2026 · After discharge or death | Overbilling | R1087 | $233.07 | $233.07 | Credited | Resolved Jun 20, 2026 |
Charges dated after discharge F2-004 · May 2026 · After discharge or death | Overbilling | R1084 | $234.25 | $234.25 | Credited | Resolved Jun 22, 2026 |
Charges dated after discharge F2-003 · May 2026 · After discharge or death | Overbilling | R1083 | $234.25 | $234.25 | Credited | Resolved Jun 23, 2026 |
Charges dated after discharge F2-002 · May 2026 · After discharge or death | Overbilling | R1088 | $267.17 | $267.17 | Credited | Resolved Jun 24, 2026 |
Charges dated after discharge F2-001 · May 2026 · After discharge or death | Overbilling | R1082 | $377.72 | $377.72 | Credited | Resolved Jul 11, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-006 · May 2026 · Payer misbilling | Overbilling | R1016 | $24.68 | $24.68 | Credited | Resolved Jul 9, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-005 · May 2026 · Payer misbilling | Overbilling | R1072 | $90.24 | $90.24 | Credited | Resolved Jun 24, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-004 · May 2026 · Payer misbilling | Overbilling | R1047 | $90.24 | $90.24 | Credited | Resolved Jul 18, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-003 · May 2026 · Payer misbilling | Overbilling | R1020 | $92.29 | $92.29 | Credited | Resolved Jun 26, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-002 · May 2026 · Payer misbilling | Overbilling | R1080 | $514.13 | $514.13 | Credited | Resolved Jul 14, 2026 |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · May 2026 · Payer misbilling | Overbilling | R1023 | $587.05 | $587.05 | Credited | Resolved Jun 18, 2026 |
Part D billed during a Medicare Part A stay C1-003 · May 2026 · Part D during Part A | Part A exposure | R1100 | $322.56 | — | Corrected | Resolved Jun 28, 2026 |
Part D billed during a Medicare Part A stay C1-002 · May 2026 · Part D during Part A | Part A exposure | R1099 | $340.48 | — | Corrected | Resolved Jun 28, 2026 |
Part D billed during a Medicare Part A stay C1-001 · May 2026 · Part D during Part A | Part A exposure | R1098 | $448.00 | — | Corrected | Resolved Jun 28, 2026 |
| No findings for this filter. | ||||||
Open disputes
Sorted by what is due first
| Finding | Resident | Amount | Credited | Status | Due |
|---|---|---|---|---|---|
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Aug 2026 · Payer misbilling | R1069 | $41.56 | $0.00 | Disputed | Oct 13, 202627 days overdue Credit expected by |
After-hours surcharge fee: fee type not listed in the pharmacy services agreement (2026-08) F4-001 · Aug 2026 · Fees against contract | Facility-level | $200.00 | $0.00 | Disputed | Oct 13, 202627 days overdue Credit expected by |
Retroactive Medicaid eligibility: credit due for charges fronted while pending F8-001 · Aug 2026 · Outside Part A | R1173 | $162.46 | $0.00 | Disputed | Oct 13, 202627 days overdue Credit expected by |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Sep 2026 · Payer misbilling | R1008 | $493.90 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
Charges dated after discharge F2-001 · Sep 2026 · After discharge or death | R1129 | $265.92 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
After-hours surcharge fee: fee type not listed in the pharmacy services agreement (2026-09) F4-001 · Sep 2026 · Fees against contract | Facility-level | $250.00 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
Possible hospice responsibility: drugs billed to the facility during hospice care F8-003 · Sep 2026 · Outside Part A | R1076 | $25.83 | $0.00 | Disputed | Nov 18, 2026in 9 days Credit expected by |
Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Oct 2026 · Payer misbilling | R1035 | $47.14 | $0.00 | Not yet disputed | Jan 29, 2027in 81 days Dispute window closes |
Duplicate charge: Lorazepam 0.5 mg TAB F3-001 · Oct 2026 · Duplicates and credits | R1169 | $22.05 | $0.00 | Not yet disputed | Jan 29, 2027in 81 days Dispute window closes |
After-hours surcharge fee: fee type not listed in the pharmacy services agreement (2026-10) F4-001 · Oct 2026 · Fees against contract | Facility-level | $150.00 | $0.00 | Not yet disputed | Jan 29, 2027in 81 days Dispute window closes |
Credits received by month
Credits matched to earlier findings, by the invoice they appeared on
How matching works
Each month we read every credit on the new invoice and tie it to an earlier finding when the resident, NDC and amount line up. A credit we cannot place is listed for review. Statuses you set by hand (disputed, denied, written off) are kept.
Credit memos needing review
Could not be tied to a finding by resident, NDC and amount
| Date | Description | Resident | Invoice | Amount | Status |
|---|---|---|---|---|---|
| Sep 18, 2026 | CREDIT MEMO - ACCOUNT ADJUSTMENT | R1004 | INV-202609 | $112.40 | Needs review |
Credits matched to findings
| Date | Finding | Credit line | Amount | Match |
|---|---|---|---|---|
| Oct 25, 2026 | Part D rejection passed to the facility: prior authorization required (avoidable rejection, review) F8-001 · Sep 2026 · Outside Part A | CREDIT MEMO - BILLING ADJ REF INV-202609 | $362.86 | Auto · exact amount |
| Oct 24, 2026 | Part D rejection passed to the facility: non-formulary (avoidable rejection, review) F8-002 · Sep 2026 · Outside Part A | CREDIT MEMO - BILLING ADJ REF INV-202609 | $240.64 | Auto · exact amount |
| Sep 25, 2026 | Charges dated after death F2-001 · Aug 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202608 | $233.00 | Auto · exact amount |
| Sep 25, 2026 | Duplicate charge: Sertraline 50 mg TAB F3-001 · Aug 2026 · Duplicates and credits | CREDIT MEMO - BILLING ADJ REF INV-202608 | $19.53 | Auto · exact amount |
| Sep 25, 2026 | OTC priced above contract: Bisacodyl 5 mg TAB EC (OTC) F8-002 · Aug 2026 · Outside Part A | CREDIT MEMO - BILLING ADJ REF INV-202608 | $1.80 | Auto · exact amount |
| Sep 13, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-002 · Jun 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202606 | $40.30 | Auto · exact amount |
| Sep 9, 2026 | Duplicate charge: Levothyroxine 50 mcg TAB F3-001 · Jun 2026 · Duplicates and credits | CREDIT MEMO - BILLING ADJ REF INV-202606 | $14.99 | Auto · exact amount |
| Sep 6, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Jun 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202606 | $493.90 | Auto · exact amount |
| Sep 5, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · Jul 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202607 | $562.36 | Auto · exact amount |
| Aug 27, 2026 | Charges dated after death F2-002 · Jul 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202607 | $233.00 | Auto · exact amount |
| Aug 27, 2026 | Duplicate charge: Aspirin 81 mg TAB EC F3-001 · Jul 2026 · Duplicates and credits | CREDIT MEMO - BILLING ADJ REF INV-202607 | $0.56 | Auto · exact amount |
| Aug 25, 2026 | Charges dated after discharge F2-002 · Jun 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202606 | $263.42 | Auto · by line |
| Aug 25, 2026 | Charges dated after discharge F2-002 · Jun 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202606 | $2.50 | Auto · by line |
| Aug 22, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-002 · Jul 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202607 | $35.98 | Auto · exact amount |
| Aug 21, 2026 | Packaging fee: fee type not listed in the pharmacy services agreement (2026-06) F4-001 · Jun 2026 · Fees against contract | CREDIT ADJ - PACKAGING FEES REF INV-202606 | $45.00 | Auto · exact amount |
| Aug 19, 2026 | CB-excluded drug billed to facility during Part A: Leuprolide Acetate 22.5 mg DEPOT KIT F5-001 · Jun 2026 · Consolidated billing | CREDIT MEMO - BILLING ADJ REF INV-202606 | $1,596.00 | Auto · exact amount |
| Aug 16, 2026 | Charges dated after discharge F2-001 · Jul 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202607 | $373.97 | Auto · by line |
| Aug 16, 2026 | Charges dated after discharge F2-001 · Jul 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202607 | $2.50 | Auto · by line |
| Aug 10, 2026 | Duplicate charge: Jardiance 10 mg TAB F3-002 · May 2026 · Duplicates and credits | CREDIT MEMO - BILLING ADJ REF INV-202605 | $325.08 | Auto · exact amount |
| Aug 4, 2026 | Delivery fee: charged above the contract rate (2026-05) F4-002 · May 2026 · Fees against contract | CREDIT ADJ - DELIVERY FEES REF INV-202605 | $100.00 | Auto · exact amount |
| Aug 4, 2026 | Delivery fee: charged above the contract rate (2026-06) F4-002 · Jun 2026 · Fees against contract | CREDIT ADJ - DELIVERY FEES REF INV-202606 | $40.00 | Auto · exact amount |
| Jul 24, 2026 | Duplicate charge: Furosemide 40 mg TAB F3-004 · May 2026 · Duplicates and credits | CREDIT MEMO - BILLING ADJ REF INV-202605 | $5.58 | Auto · exact amount |
| Jul 23, 2026 | Charges dated after discharge F2-006 · May 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202605 | $226.01 | Auto · exact amount |
| Jul 22, 2026 | Charges dated after discharge F2-001 · Jun 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202606 | $265.92 | Auto · exact amount |
| Jul 21, 2026 | Duplicate charge: Amlodipine 5 mg TAB F3-002 · Jun 2026 · Duplicates and credits | CREDIT MEMO - BILLING ADJ REF INV-202606 | $11.48 | Auto · exact amount |
| Jul 20, 2026 | Packaging fee: fee type not listed in the pharmacy services agreement (2026-05) F4-004 · May 2026 · Fees against contract | CREDIT ADJ - PACKAGING FEES REF INV-202605 | $45.00 | Auto · exact amount |
| Jul 20, 2026 | Priced above contract: Eliquis 5 mg TAB F6-001 · Jun 2026 · Price against contract | CREDIT MEMO - BILLING ADJ REF INV-202606 | $35.28 | Auto · by line |
| Jul 20, 2026 | Priced above contract: Eliquis 5 mg TAB F6-001 · Jun 2026 · Price against contract | CREDIT MEMO - BILLING ADJ REF INV-202606 | $28.22 | Auto · by line |
| Jul 20, 2026 | Priced above contract: Eliquis 5 mg TAB F6-001 · Jun 2026 · Price against contract | CREDIT MEMO - BILLING ADJ REF INV-202606 | $23.52 | Auto · by line |
| Jul 20, 2026 | Priced above contract: Eliquis 5 mg TAB F6-001 · Jun 2026 · Price against contract | CREDIT MEMO - BILLING ADJ REF INV-202606 | $18.82 | Auto · by line |
| Jul 20, 2026 | Priced above contract: Eliquis 5 mg TAB F6-001 · Jun 2026 · Price against contract | CREDIT MEMO - BILLING ADJ REF INV-202606 | $43.51 | Auto · by line |
| Jul 19, 2026 | Duplicate charge: Donepezil 10 mg TAB F3-003 · May 2026 · Duplicates and credits | CREDIT MEMO - BILLING ADJ REF INV-202605 | $27.72 | Auto · exact amount |
| Jul 19, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-003 · Jun 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202606 | $40.30 | Auto · exact amount |
| Jul 18, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-004 · May 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202605 | $90.24 | Auto · exact amount |
| Jul 16, 2026 | Charges dated after discharge F2-003 · Jun 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202606 | $222.26 | Auto · by line |
| Jul 16, 2026 | Charges dated after discharge F2-003 · Jun 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202606 | $2.50 | Auto · by line |
| Jul 14, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-002 · May 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202605 | $514.13 | Auto · exact amount |
| Jul 11, 2026 | Charges dated after discharge F2-001 · May 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202605 | $373.97 | Auto · by line |
| Jul 11, 2026 | Charges dated after discharge F2-001 · May 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202605 | $3.75 | Auto · by line |
| Jul 9, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-006 · May 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202605 | $24.68 | Auto · exact amount |
| Jul 9, 2026 | CB-excluded drug billed to facility during Part A: Leuprolide Acetate 22.5 mg DEPOT KIT F5-001 · May 2026 · Consolidated billing | CREDIT MEMO - BILLING ADJ REF INV-202605 | $1,596.00 | Auto · exact amount |
| Jul 7, 2026 | Priced above contract: Pantoprazole 40 mg TAB EC F6-001 · May 2026 · Price against contract | CREDIT MEMO - BILLING ADJ REF INV-202605 | $19.84 | Auto · by line |
| Jul 7, 2026 | Priced above contract: Pantoprazole 40 mg TAB EC F6-001 · May 2026 · Price against contract | CREDIT MEMO - BILLING ADJ REF INV-202605 | $19.84 | Auto · by line |
| Jul 7, 2026 | Priced above contract: Pantoprazole 40 mg TAB EC F6-001 · May 2026 · Price against contract | CREDIT MEMO - BILLING ADJ REF INV-202605 | $19.84 | Auto · by line |
| Jul 7, 2026 | Priced above contract: Pantoprazole 40 mg TAB EC F6-001 · May 2026 · Price against contract | CREDIT MEMO - BILLING ADJ REF INV-202605 | $19.84 | Auto · by line |
| Jul 7, 2026 | Priced above contract: Pantoprazole 40 mg TAB EC F6-001 · May 2026 · Price against contract | CREDIT MEMO - BILLING ADJ REF INV-202605 | $19.84 | Auto · by line |
| Jul 7, 2026 | Priced above contract: Pantoprazole 40 mg TAB EC F6-001 · May 2026 · Price against contract | CREDIT MEMO - BILLING ADJ REF INV-202605 | $19.84 | Auto · by line |
| Jul 5, 2026 | Dispensing fee: charged above the contract rate (2026-05) F4-001 · May 2026 · Fees against contract | CREDIT ADJ - DISPENSING FEES REF INV-202605 | $365.00 | Auto · exact amount |
| Jun 26, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-003 · May 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202605 | $88.54 | Auto · by line |
| Jun 26, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-003 · May 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202605 | $3.75 | Auto · by line |
| Jun 24, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-005 · May 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202605 | $90.24 | Auto · exact amount |
| Jun 24, 2026 | Charges dated after discharge F2-002 · May 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202605 | $263.42 | Auto · by line |
| Jun 24, 2026 | Charges dated after discharge F2-002 · May 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202605 | $3.75 | Auto · by line |
| Jun 23, 2026 | Charges dated after discharge F2-003 · May 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202605 | $230.50 | Auto · by line |
| Jun 23, 2026 | Charges dated after discharge F2-003 · May 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202605 | $3.75 | Auto · by line |
| Jun 22, 2026 | Charges dated after discharge F2-004 · May 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202605 | $234.25 | Auto · exact amount |
| Jun 22, 2026 | CB-excluded drug billed to facility during Part A: Epoetin Alfa 10,000 unit/mL VIAL F5-002 · May 2026 · Consolidated billing | CREDIT MEMO - BILLING ADJ REF INV-202605 | $117.60 | Auto · exact amount |
| Jun 20, 2026 | Charges dated after discharge F2-005 · May 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202605 | $229.32 | Auto · by line |
| Jun 20, 2026 | Charges dated after discharge F2-005 · May 2026 · After discharge or death | CREDIT MEMO - BILLING ADJ REF INV-202605 | $3.75 | Auto · by line |
| Jun 18, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · May 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202605 | $583.30 | Auto · by line |
| Jun 18, 2026 | Billed to facility while resident's drugs were the responsibility of Medicaid / Part D plan F1-001 · May 2026 · Payer misbilling | CREDIT MEMO - BILLING ADJ REF INV-202605 | $3.75 | Auto · by line |
| Jun 18, 2026 | Duplicate charge: Eliquis 5 mg TAB F3-001 · May 2026 · Duplicates and credits | CREDIT MEMO - BILLING ADJ REF INV-202605 | $510.38 | Auto · exact amount |
Routine return credits
Credits for returned medication, shown for completeness
| Month | Credit lines | Amount |
|---|---|---|
| October 2026 | 133 | $7,500.84 |
| September 2026 | 80 | $4,696.70 |
| August 2026 | 108 | $6,361.25 |
| July 2026 | 88 | $7,332.27 |
| June 2026 | 103 | $9,190.14 |
| May 2026 | 128 | $7,633.92 |
Part A exposure by month
Drugs billed to Part D while the resident was in a facility-responsible Part A stay
What this is
For residents in a Medicare Part A stay, the facility is responsible for their drugs. When the pharmacy bills a Part D plan instead, the claim is improper. This is the pattern behind OIG audit A-09-21-03008. These items are a billing correction, not a credit: the pharmacy reverses the Part D claim and bills the facility. We track each one until it is corrected.
Exposure items
| Finding | Type | Resident | Amount | Credited | Status | Due / resolved |
|---|---|---|---|---|---|---|
Part D billed during a Medicare Part A stay C1-001 · Oct 2026 · Part D during Part A | Part A exposure | R1163 | $407.68 | — | Needs correction | — |
Part D billed during a Medicare Part A stay C1-001 · Sep 2026 · Part D during Part A | Part A exposure | R1149 | $661.44 | — | Needs correction | — |
Part D billed during a Medicare Part A stay C1-001 · Aug 2026 · Part D during Part A | Part A exposure | R1134 | $483.60 | — | Corrected | Resolved Sep 29, 2026 |
Part D billed during a Medicare Part A stay C1-001 · Jul 2026 · Part D during Part A | Part A exposure | R1121 | $465.92 | — | Corrected | Resolved Aug 27, 2026 |
Part D billed during a Medicare Part A stay C1-002 · Jun 2026 · Part D during Part A | Part A exposure | R1110 | $341.76 | — | Corrected | Resolved Jul 29, 2026 |
Part D billed during a Medicare Part A stay C1-001 · Jun 2026 · Part D during Part A | Part A exposure | R1111 | $508.80 | — | Corrected | Resolved Jul 29, 2026 |
Part D billed during a Medicare Part A stay C1-003 · May 2026 · Part D during Part A | Part A exposure | R1100 | $322.56 | — | Corrected | Resolved Jun 28, 2026 |
Part D billed during a Medicare Part A stay C1-002 · May 2026 · Part D during Part A | Part A exposure | R1099 | $340.48 | — | Corrected | Resolved Jun 28, 2026 |
Part D billed during a Medicare Part A stay C1-001 · May 2026 · Part D during Part A | Part A exposure | R1098 | $448.00 | — | Corrected | Resolved Jun 28, 2026 |
| No findings for this filter. | ||||||
Monthly uploads
Each upload runs the full audit
| Month | Files | Audited | Invoice lines | Findings | Status |
|---|---|---|---|---|---|
| October 2026 | Northbridge billing detail Oct 2026.csvreceived Nov 6 · 1,236 lines Census activity Oct 2026.csvreceived Nov 9 · 173 residents | Nov 9, 2026 | 1,236 | 4 | Audited |
| September 2026 | Northbridge billing detail Sep 2026.csvreceived Oct 8 · 1,176 lines Census activity Sep 2026.csvreceived Oct 15 · 162 residents | Oct 15, 2026 | 1,176 | 7 | Audited |
| August 2026 | Northbridge billing detail Aug 2026.csvreceived Sep 8 · 1,168 lines Census activity Aug 2026.csvreceived Sep 9 · 148 residents PSA Amendment 1 (STAT delivery).pdfreceived Sep 8 | Sep 9, 2026 | 1,168 | 7 | Audited |
| July 2026 | Northbridge billing detail Jul 2026.csvreceived Aug 6 · 1,080 lines Census activity Jul 2026.csvreceived Aug 7 · 132 residents | Aug 7, 2026 | 1,080 | 6 | Audited |
| June 2026 | Northbridge billing detail Jun 2026.csvreceived Jul 7 · 1,120 lines Census activity Jun 2026.csvreceived Jul 9 · 119 residents | Jul 9, 2026 | 1,120 | 14 | Audited |
| May 2026 | Northbridge billing detail May 2026.csvreceived Jun 5 · 1,232 lines Census activity May 2026.csvreceived Jun 8 · 107 residents | Jun 8, 2026 | 1,232 | 26 | Audited |
Checklist
- Nov 2026Due Dec 10
- Oct 2026Invoices · Nov 6 Census · Nov 9
- Sep 2026Invoices · Oct 8 Census · late Oct 15
- Aug 2026Invoices · Sep 8 Census · Sep 9
- Jul 2026Invoices · Aug 6 Census · Aug 7
- Jun 2026Invoices · Jul 7 Census · Jul 9
- May 2026Invoices · Jun 5 Census · Jun 8
Fee schedule in force
PSA-2025-014 · effective Jan 1, 2025
| Fee | Rate | Unit | Monthly cap | Clause |
|---|---|---|---|---|
| Dispensing | $2.50 | per rx | — | Exhibit B §2.1 (Dispensing Fee) |
| Delivery | $0.00 | per delivery | — | Exhibit B §2.2 (Delivery) |
| STAT delivery | $45.00 was $35.00 | per delivery | 4 | Exhibit B §2.3 (STAT Delivery), as amended by Amendment 1 |
| E-kit | $150.00 | per month | 1 | Exhibit B §2.4 (Emergency Kit) |
| IV administration | $75.00 | per day | — | Exhibit C §1 (Infusion Services) |
- Pricing
- Exhibit B §1 (Drug Pricing): brand AWP less 16%; generic AWP less 55%
- Unlisted fees
- Not allowed: Exhibit B §2 (Fees): no fees other than those listed
- Disputes
- §9.2 (Invoice Disputes): disputes within 90 days of invoice date
- Billing responsibility
- §5.1 (Billing Responsibility): pharmacy bills facility only for residents in a covered Part A or managed-care stay; all others to the applicable third party
Amendments
- Amendment 1 · effective Aug 1, 2026STAT delivery fee raised from $35.00 to $45.00 per delivery; monthly cap unchanged at 4. No other fees added.
Contract watch
Changes and patterns we are tracking
- New fee patternAfter-hours surcharge billed since August 2026; not in the agreement$600.00 flagged across 3 months, $0.00 credited. The agreement does not list this fee or allow unlisted fees. Raise it with the pharmacy at contract level, not only invoice by invoice.
- Amendment 1STAT delivery fee raised from $35.00 to $45.00 (+29%)In force from August 2026. 9 billed since, $90.00 more than the old rate. Every charge since matches the amended rate and monthly cap.
- Credits overdue3 disputed items past the 30-day credit follow-up$404.02 still owed. Follow up with the pharmacy's billing contact.
Monthly reports
One report per month, with dispute letters for each finding
| Report | Delivered | Overbilling | Part A exposure | |
|---|---|---|---|---|
Monitoring report · October 2026 Findings, dispute letters, credit check | Nov 9, 2026 | $219.19 | $407.68 | Delivered to the client portal |
Monitoring report · September 2026 Findings, dispute letters, credit check | Oct 15, 2026 | $1,639.15 | $661.44 | Delivered to the client portal |
Monitoring report · August 2026 Findings, dispute letters, credit check | Sep 9, 2026 | $658.35 | $483.60 | Delivered to the client portal |
Monitoring report · July 2026 Findings, dispute letters, credit check | Aug 7, 2026 | $1,208.37 | $465.92 | Delivered to the client portal |
Monitoring report · June 2026 Findings, dispute letters, credit check | Jul 9, 2026 | $3,187.92 | $850.56 | Delivered to the client portal |
Monitoring report · May 2026 Findings, dispute letters, credit check | Jun 8, 2026 | $6,328.66 | $1,111.04 | Delivered to the client portal |